TCT-885
Transcatheter Aortic Valve Implantation with Medtronic CoreValve® Versus Medtronic CoreValve® with Accutrac Delivery System
Gill Buchanan1, Alaide Chieffo1, Matteo Montorfano1, Francesco Maisano1, Azem Latib1, Micaela Cioni1, Filippo Fignini1, Francesco Giannini1, Chiara Bernelli1, Alessandro Durante1, Santo Ferrarello1, Mauro Carlino1, Pietro Spagnolo1, Annalisa Francus1, Chiara Gerli1, Remo Covello1, Enrico La Agnol1, Giovanni La Cam1, Ottavio Alfieri1, Antonio Colomb1, 2San Raffaele Scientific Institute, Milan, Italy, 3San Raffaele Scientific Institute, Milan, N/A

Background: The Medtronic CoreValve® with Accutrac delivery system (MCVAT) (Medtronic Inc., Minneapolis, MN) was introduced to aid deliverability. The aim was to compare short-term outcomes after transcatheter aortic valve implantation (TAVI) with both the original Medtronic CoreValve® delivery system (MCV) vs. the MCVAT. Analyses were performed in patients with severe aortic stenosis undergoing transfemoral TAVI in our center from November 2007-May 2012 with either MCV or MCVAT were included. The 31 mm MCVAT became available in September 2011. Study objectives were the Valve Academic Research Consortium (VARC) outcomes.

Results: In total, 125 TAVI cases were included: 56% (n = 70) MCV and 44% (n = 55) MCVAT. There was a trend for patients treated with MCV to be older (79.7 ± 6.7 vs. 77.5 ± 6.9 years; p = 0.072), but no other differences in baseline characteristics. Logistic EuroSCORE was respectively 24.6 ± 16.5% in MCV vs. 24.0 ± 16.5% in MCVAT (p = 0.569) and STS score 9.3 ± 9.6% vs. 8.7 ± 8.2% (p = 0.713). At 30 days, there were no differences between MCV and MCVAT respectively in all-cause (7.1% vs. 5.6%; p = 0.721) or cardiovascular mortality (2.9% vs. 5.6%; p = 0.449). In addition, myocardial infarction (2.9% vs. 0%; p = 0.206) and stroke (0 vs. 1.8%; p = 0.257) were similar. However, there were improvements in major vascular complications (17.1% vs. 5.6%; p = 0.017), life-threatening bleeding (32.9% vs. 16.4%; p = 0.036) and acute kidney injury (44.3% vs. 20.4%; p = 0.005), leading to an improved combined safety endpoint (40.0% vs. 22.6%; p = 0.042). Interestingly, there was an increase in arrhythmia (18.6% vs. 49.1%; p < 0.001) and permanent pacemaker implantation (21.4% vs. 41.8%; p = 0.014) in the MCVAT group. There were no differences in the event of embolization (7.1% vs. 12.7%; p = 0.293) or moderate-severe aortic regurgitation (5.7% vs. 5.7%; p = 0.990) Furthermore, there was no difference in death (0.0% vs. 8.5%; p = 0.438).

Conclusions: The MCVAT has improved safety endpoints compared to MCV, probably due to the learning curve. However, there is a higher rate of arrhythmia and PPM in this group, possibly due to the introduction of the 31 mm valve. Longer term follow-up and larger patient numbers are required.

TCT-886
Predictors of Vascular complications in patients undergoing Balloon Aortic Valvuloplasty
Anoopa Kini1, Rosana Mehran2, Nilasha Gukathasan3, Ziad Sergie4, Valvuloplasty

Background: Balloon aortic valvuloplasty (BAV) is a palliative treatment for severe aortic stenosis (AS) that is increasingly performed as a bridge to transcatheter aortic valve replacement. We investigated the independent predictors of vascular complications in AS patients who underwent BAV. Methods: We performed a retrospective review of consecutive patients who undergoing non-emergent, retrograde BAV at two high-volume US centers. We analyzed baseline and procedural characteristics as well as in-hospital outcomes according to the presence or absence of vascular complications, as classified by the Vascular Academic Research Consortium (VARC). Net adverse clinical events (NACE) were defined as composite of absence of vascular complications, as classified by the Vascular Academic Research Consortium (VARC). Results: Among 428 BAV patients, the average age was 83 ± 9 years and 30 (7.0%) had vascular complications. Patients with vs. without vascular complications had higher rates of myocardial infarction (13.3% vs. 2.5%; p = 0.001), stroke (6.7% vs. 0.3%; p < 0.001), and NACE (33.3% vs. 9.8%; p < 0.001). Multivariable adjusted predictors of vascular complications are shown in the Figure.

Conclusions: In this large registry of BAV patients, pre-closure failure, thrombocytopenia and concurrent PCI were associated with worsened risk of complications in patients undergoing BAV.